Key Takeaways
Extended Takeaways
- Dose-optimized guanfacine extended-release showed separation from placebo by week 4 on the ADHD-RS-IV total score, with benefits sustained through week 10, suggesting clinicians should allow several weeks of titration before judging efficacy.
- The signal was not limited to inattentive symptoms: ADHD-RS-IV inattention improved by -7.39 ± 0.79 versus -4.89 ± 0.76 and hyperactivity-impulsivity improved by -3.84 ± 0.54 versus -2.10 ± 0.52, supporting use when both symptom domains remain clinically relevant in adult ADHD.
- Functional gains were selective rather than global: on the Adult ADHD Quality of Life Questionnaire, only the life productivity subscale reached significance (P = .0072), and on the BRIEF-A, significant improvement was seen for Inhibit, Initiate, Plan/Organize, and Global Executive Composite Index subscales.
- Tolerability issues clustered early in treatment. Many somnolence events occurred within the first week, and discontinuations due to blood pressure decrease or somnolence occurred during the dose-optimization period, making early follow-up during titration especially important.
- This trial excluded adults with schizophrenia, bipolar disorder, personality disorder, documented anxiety/depression requiring treatment, substance use disorder history, seizures, serious tic disorder, suicide risk, or cardiovascular abnormalities, so the results are most applicable to relatively psychiatrically and medically uncomplicated adult ADHD.
- Mean guanfacine extended-release dose during maintenance was 5.07 mg, with 27 patients on 4 mg, 23 patients on 5 mg, and 33 patients on 6 mg, which supports individualized dosing within the 4-6 mg/d range rather than assuming all adults need the maximum dose.
